Faes’ Q2 results witnessed a strong performance in the LatAm markets, being largely offset by the weaknesses in Spain and the Animal healthcare business, and subdued growth in the Licensing business. Drug-wise, Bilastine and Calcifediol’s healthy growth made up for the underperformance in other medicines. The full-year guidance remained unchanged. Overall, while Bilastine’s recent years’ patent expiries have weighed on the share price, we remain optimistic on Faes, banking on Bilastine’s life-cy ....
